184 related articles for article (PubMed ID: 28394898)
1. Prognostic and clinicopathological value of GATA binding protein 3 in breast cancer: A systematic review and meta-analysis.
Guo Y; Yu P; Liu Z; Maimaiti Y; Chen C; Zhang Y; Yin X; Wang S; Liu C; Huang T
PLoS One; 2017; 12(4):e0174843. PubMed ID: 28394898
[TBL] [Abstract][Full Text] [Related]
2. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
[TBL] [Abstract][Full Text] [Related]
3. GATA3 expression and its relationship with clinicopathological parameters in invasive breast carcinomas.
Cakir A; Isik Gonul I; Ekinci O; Cetin B; Benekli M; Uluoglu O
Pathol Res Pract; 2017 Mar; 213(3):227-234. PubMed ID: 28215639
[TBL] [Abstract][Full Text] [Related]
4. Cytokeratin 7-negative and GATA binding protein 3-negative breast cancers: Clinicopathological features and prognostic significance.
Lu S; Yakirevich E; Wang LJ; Resnick MB; Wang Y
BMC Cancer; 2019 Nov; 19(1):1085. PubMed ID: 31718619
[TBL] [Abstract][Full Text] [Related]
5. Association Between Estrogen Receptors and GATA3 in Bladder Cancer: A Systematic Review and Meta-Analysis of Their Clinicopathological Significance.
Bernardo C; Monteiro FL; Direito I; Amado F; Afreixo V; Santos LL; Helguero LA
Front Endocrinol (Lausanne); 2021; 12():684140. PubMed ID: 34690921
[TBL] [Abstract][Full Text] [Related]
6. Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions:: A Cell-Block Microarray Study.
El Hag MI; Ha J; Farag R; El Hag AM; Michael CW
Diagn Cytopathol; 2016 Sep; 44(9):731-6. PubMed ID: 27338760
[TBL] [Abstract][Full Text] [Related]
7. GATA-binding protein 3, gross cystic disease fluid protein-15 and mammaglobin have distinct prognostic implications in different invasive breast carcinoma subgroups.
Ni YB; Tsang JY; Chan SK; Tse GM
Histopathology; 2015 Jul; 67(1):96-105. PubMed ID: 25425335
[TBL] [Abstract][Full Text] [Related]
8. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.
Mehra R; Varambally S; Ding L; Shen R; Sabel MS; Ghosh D; Chinnaiyan AM; Kleer CG
Cancer Res; 2005 Dec; 65(24):11259-64. PubMed ID: 16357129
[TBL] [Abstract][Full Text] [Related]
9. Expression Pattern of Smad4/GATA3 as a Predictor of Survival in Invasive Ductal Carcinoma of the Breast.
Min KW; Kim DH; Do SI; Chae SW; Kim K; Sohn JH; Lee HJ; Do IG; Pyo JS; Kim Y; Kim DH; Yang JH; Lee SJ; Oh YH; Oh S; Choi SH; Park YL; Park CH; Kim EK; Kwon MJ; Seo J
Pathobiology; 2017; 84(3):130-138. PubMed ID: 28288473
[TBL] [Abstract][Full Text] [Related]
10. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
Yang Y; Lu S; Zeng W; Xie S; Xiao S
Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.
Guo Y; Yu P; Liu Z; Maimaiti Y; Wang S; Yin X; Liu C; Huang T
PLoS One; 2016; 11(5):e0156323. PubMed ID: 27227453
[TBL] [Abstract][Full Text] [Related]
12. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value.
Voduc D; Cheang M; Nielsen T
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):365-73. PubMed ID: 18268121
[TBL] [Abstract][Full Text] [Related]
13. GATA3 somatic mutations are associated with clinicopathological features and expression profile in TCGA breast cancer patients.
Afzaljavan F; Sadr AS; Savas S; Pasdar A
Sci Rep; 2021 Jan; 11(1):1679. PubMed ID: 33462316
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis.
Li X; Li M; Lian Z; Zhu H; Kong L; Wang P; Yu J
Target Oncol; 2016 Dec; 11(6):753-761. PubMed ID: 27422273
[TBL] [Abstract][Full Text] [Related]
15. GATA3 expression in advanced breast cancer: prognostic value and organ-specific relapse.
McCleskey BC; Penedo TL; Zhang K; Hameed O; Siegal GP; Wei S
Am J Clin Pathol; 2015 Nov; 144(5):756-63. PubMed ID: 26486740
[TBL] [Abstract][Full Text] [Related]
16. Higher levels of GATA3 predict better survival in women with breast cancer.
Yoon NK; Maresh EL; Shen D; Elshimali Y; Apple S; Horvath S; Mah V; Bose S; Chia D; Chang HR; Goodglick L
Hum Pathol; 2010 Dec; 41(12):1794-801. PubMed ID: 21078439
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and clinicopathological value of poly (adenosine diphosphate-ribose) polymerase expression in breast cancer: A meta-analysis.
Qiao W; Pan L; Kou C; Li K; Yang M
PLoS One; 2017; 12(2):e0172413. PubMed ID: 28212434
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and clinicopathological significance of cyclin B expression in patients with breast cancer: A meta-analysis.
Sun X; Zhangyuan G; Shi L; Wang Y; Sun B; Ding Q
Medicine (Baltimore); 2017 May; 96(19):e6860. PubMed ID: 28489780
[TBL] [Abstract][Full Text] [Related]
19. DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.
Ansems M; Hontelez S; Looman MW; Karthaus N; Bult P; Bonenkamp JJ; Jansen JH; Sweep FC; Span PN; Adema GJ
J Natl Cancer Inst; 2010 Jan; 102(1):54-68. PubMed ID: 20008677
[TBL] [Abstract][Full Text] [Related]
20. Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors.
Gulbahce HE; Sweeney C; Surowiecka M; Knapp D; Varghese L; Blair CK
Hum Pathol; 2013 Nov; 44(11):2427-31. PubMed ID: 23998430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
